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The management of rectal  cancer has seen major 
developments over the last few decades (1) with increasing 
use of pre-operative imaging for local staging, more clear 
role for neoadjuvant chemoradiotherapy (nCRT) (2) 
and standardization of radical local resection with total 
mesorectal excision (TME) surgery which resulted in 
reduction of local recurrence rate to less than 10% (3). 
However, it has been increasingly recognized that patients 
with locally advanced low rectal cancer represent a 
particular challenge in terms of local disease control (4). 
This subgroup of patients is now known to have lateral 
pelvic lymph node (LPLN) metastasis in 15% to 20% 
which results in poor survival rates due to an increased risk 
of local and distant recurrence (5).
In the Western world, patients who have LPLN on initial 
staging scans are considered to have distant metastasis and 
offered nCRT followed by TME resection (6). However, 
in Japan these patients are considered to have local disease 
and therefore they are offered TME surgery with bilateral 
LPLND (4). Unfortunately, each of those treatment 
strategies has its own shortcomings. On one hand, there 
are studies to suggest that nCRT does not completely 
eradicate LPLN metastasis (7) with some evidence to show 
an almost linear relationship between lymph node size 
on the initial staging scans and local recurrence rates (4). 
Moreover, radiation therapy is associated with risks of 
radiation enteritis and secondary cancers (6). On the other 
hand, LPLND increases the morbidity from surgery with 
increased operating time, intraoperative blood loss, higher 
possibility of urinary and sexual dysfunction with lack of 
definitive evidence of better oncologic outcomes following 
such morbid procedure (8).
There is  an ongoing debate on what should be 
considered as suspicious lymph nodes and what criteria to 
use to make such diagnosis (4). Most of the studies use a size 
and/or morphology criteria to diagnose suspicious lymph 
nodes in the context of low rectal cancer (9). However, 
there is no agreement on the cut off size to what should be 
called suspicious LPLN on preoperative imaging as this 
ranges from 5 to 10 mm in the short axis between various 
studies (6). Morphological criteria for suspected LPLN 
metastasis include lymph nodes contour irregularity and 
signal intensity disparity (10). There is some evidence to 
support that lymph node size greater than 1cm in short axis 
in pre-treatment imaging is a better predictive of LPLN 
metastasis more than morphological features (11,12).
There are evolving imaging modalities to improve the 
accuracy of predicting suspicious LPLN on staging scans 
which include magnetic resonance diffusion-weighted 
imaging (DWI), lymph node-specific contrast agents and 
positron emission tomography computed tomography 
(PET-CT) (9). DWI could be a reliable predictor of yN0 
status following nCRT with positive predictive value of 
24% and the negative predictive value of 100% (13). MRI 
with a lymph node-specific contrast agent has shown high 
negative predictive value for of LPLN metastasis (14). PET 
CT can predict the presence of LPLN metastasis with 
increased accuracy and therefore it could be used to select 
patients that might benefit from LPLND (15).
The exact role of LPLND in the management of locally 
advanced low rectal cancer has to be defined. Should we 
offer routine ‘prophylactic’ LPLND in all patients with 
locally advanced disease (4) or only use selective approach 
to treat patients with suspicious LPLN on preoperative 
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imaging (5). Also, it is not clear if patients should be offered 
LPLND based on the findings on the initial staging scans 
regardless the findings on restaging imaging (5) or only for 
patients who have persistent suspicious LPLN on restaging 
scans following nCRT (7). There is some evidence to 
suggest that involved LPLN in preoperative MRI increases 
local recurrence rates despite clinical or pathological 
response seen on re-staging scans after nCRT (16). 
However, there is also contradicting data to suggest that 
disease-free survival is not different between those who were 
suspected to have LPLN metastasis and those who were 
not following standard TME surgery if the patients had 
nCRT (7). Therefore some believe that LPLN metastasis is 
not an independent risk factor in low rectal cancer but it is 
rather a reflection of an adverse feature of the disease.
The traditional open approach for LPLND seems to 
declining with growing number of publications using 
minimally invasive approach for LPLND including 
laparoscopic (17-19), robotic (20,21) and transanal 
robotic (22) with increasing emphasis on nerve preserving 
surgery (23). However, it is clear from the available literature 
that experience in the Western world with LPLND is still 
limited (24).
It is likely that the next decade will witness a better 
agreement on the prognostic significance of LPLN, imaging 
criteria on what should be considered as suspicious LPLN, 
whether LPLND should be offered routinely or selectively, 
better delineation on the interface between LPLND and 
nCRT as well as the optimal operative approach for the 
procedure. 
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